At a Glance

  • Pure-play clinical stage therapeutics development company
  • Two technology platforms on which to build
    • T regulatory cells for immune modulation
    • CD34+ cells for ischemic repair
  • Well-funded with cash on hand >~$60 million
  • Debt-free
  • On-going landmark phase 2 study of CLBS03 in recent onset type 1 diabetes
    • Strategic relationship with Sanford Research (CLBS retains all product rights)
    • ~$12.2 million CIRM grant awarded
    • ~$600,000 JDRF study subsidy
  • Phase 2 protocol in Critical Limb Ischemia for CLBS12 initiated in Japan
    • Positive results should qualify product for early conditional approval in Japan

Sign up to our e-mail list to receive Caladrius announcements.

Stock Chart

Maximum 30 minute delay for quote.

Investor & Media Contact

Caladrius Biosciences, Inc.
John D. Menditto
Executive Director
Investor Relations & Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com